Logo image of AKLI

AKILI INC (AKLI) Stock Fundamental Analysis

NASDAQ:AKLI - Nasdaq - US00974B1070 - Common Stock - Currency: USD

0.432  0 (-0.62%)

Fundamental Rating

2

AKLI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 36 industry peers in the Health Care Technology industry. While AKLI seems to be doing ok healthwise, there are quite some concerns on its profitability. AKLI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AKLI has reported negative net income.
AKLI had a negative operating cash flow in the past year.
AKLI Yearly Net Income VS EBIT VS OCF VS FCFAKLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -72.07%, AKLI is doing worse than 71.79% of the companies in the same industry.
AKLI has a Return On Equity of -96.70%. This is in the lower half of the industry: AKLI underperforms 61.54% of its industry peers.
Industry RankSector Rank
ROA -72.07%
ROE -96.7%
ROIC N/A
ROA(3y)-81.25%
ROA(5y)N/A
ROE(3y)-103.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKLI Yearly ROA, ROE, ROICAKLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

AKLI's Gross Margin of 55.97% is in line compared to the rest of the industry. AKLI outperforms 48.72% of its industry peers.
AKLI's Gross Margin has declined in the last couple of years.
AKLI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.94%
GM growth 5YN/A
AKLI Yearly Profit, Operating, Gross MarginsAKLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

AKLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKLI has more shares outstanding than it did 1 year ago.
AKLI has a worse debt/assets ratio than last year.
AKLI Yearly Shares OutstandingAKLI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M
AKLI Yearly Total Debt VS Total AssetsAKLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -6.99, we must say that AKLI is in the distress zone and has some risk of bankruptcy.
AKLI's Altman-Z score of -6.99 is on the low side compared to the rest of the industry. AKLI is outperformed by 84.62% of its industry peers.
AKLI has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.08, AKLI is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -6.99
ROIC/WACCN/A
WACC11.29%
AKLI Yearly LT Debt VS Equity VS FCFAKLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 5.80 indicates that AKLI has no problem at all paying its short term obligations.
AKLI's Current ratio of 5.80 is amongst the best of the industry. AKLI outperforms 87.18% of its industry peers.
A Quick Ratio of 5.80 indicates that AKLI has no problem at all paying its short term obligations.
AKLI has a Quick ratio of 5.80. This is amongst the best in the industry. AKLI outperforms 87.18% of its industry peers.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.8
AKLI Yearly Current Assets VS Current LiabilitesAKLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AKLI have decreased strongly by -242.57% in the last year.
AKLI shows a strong growth in Revenue. In the last year, the Revenue has grown by 439.44%.
The Revenue for AKLI have been decreasing by -24.76% on average. This is quite bad
EPS 1Y (TTM)-242.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
Revenue 1Y (TTM)439.44%
Revenue growth 3Y-24.76%
Revenue growth 5YN/A
Sales Q2Q%238.94%

3.2 Future

Based on estimates for the next years, AKLI will show a small growth in Earnings Per Share. The EPS will grow by 5.00% on average per year.
AKLI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 194.84% yearly.
EPS Next Y19.97%
EPS Next 2Y13.06%
EPS Next 3Y8.08%
EPS Next 5Y5%
Revenue Next Year94.59%
Revenue Next 2Y73.98%
Revenue Next 3Y66.56%
Revenue Next 5Y194.84%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AKLI Yearly Revenue VS EstimatesAKLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
AKLI Yearly EPS VS EstimatesAKLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKLI Price Earnings VS Forward Price EarningsAKLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKLI Per share dataAKLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.06%
EPS Next 3Y8.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKILI INC

NASDAQ:AKLI (7/1/2024, 8:18:36 PM)

0.432

0 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-14 2024-05-14/amc
Earnings (Next)08-08 2024-08-08/amc
Inst Owners29.77%
Inst Owner Change0%
Ins Owners0.5%
Ins Owner Change0%
Market Cap34.01M
Analysts43.33
Price Target0.66 (52.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.3%
Min EPS beat(2)15.97%
Max EPS beat(2)34.64%
EPS beat(4)4
Avg EPS beat(4)20.07%
Min EPS beat(4)7.12%
Max EPS beat(4)34.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-30.46%
Min Revenue beat(2)-52.71%
Max Revenue beat(2)-8.21%
Revenue beat(4)1
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-53.17%
Max Revenue beat(4)113.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.51
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.02
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.07%
ROE -96.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.97%
FCFM N/A
ROA(3y)-81.25%
ROA(5y)N/A
ROE(3y)-103.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.94%
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.59%
Cap/Sales 19.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.8
Quick Ratio 5.8
Altman-Z -6.99
F-Score3
WACC11.29%
ROIC/WACCN/A
Cap/Depr(3y)78.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)37.25%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-242.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
EPS Next Y19.97%
EPS Next 2Y13.06%
EPS Next 3Y8.08%
EPS Next 5Y5%
Revenue 1Y (TTM)439.44%
Revenue growth 3Y-24.76%
Revenue growth 5YN/A
Sales Q2Q%238.94%
Revenue Next Year94.59%
Revenue Next 2Y73.98%
Revenue Next 3Y66.56%
Revenue Next 5Y194.84%
EBIT growth 1Y36.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.09%
EBIT Next 3Y12.53%
EBIT Next 5Y10.27%
FCF growth 1Y29.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.02%
OCF growth 3YN/A
OCF growth 5YN/A